# CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

> **NCT07328503** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- B-All

## Interventions

- **BIOLOGICAL:** CD22 CAR-transduced T cells
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT07328503
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2030-01-31
- **Final completion:** 2031-01-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07328503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07328503, "CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT07328503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*